Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset THC

Coverage 92,282 Raw stories ingested 7,953 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,727 Assets with fetched stories

Cryptocurrencies BTC 4,247 ETH 3,075 SOL 1,751 XRP 1,686 USDC 965 HYPE 822

Stocks SPCX 879 MU 723 NVDA 684 MSFT 557 GOOGL 531 TSLA 504

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 147 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,679 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 53s ago
FMP Forex News Fetch every 5 min 3m ago
CoinGecko News Fetch every 5 min 3m ago
FIO Stock News Fetch every 10 min 2m ago
Patria Stock News Fetch every 10 min 2m ago
Editorial rewrite Rewrite every minute 53s ago
Asset sync Assets every 1 hour 32m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-24 00:52 2d ago Published 2026-07-23 19:21 2d ago	Tenet Healthcare překonala odhady zisku i tržeb Tenet Healthcare ve 2. čtvrtletí vykázala zisk na akcii 6,12 USD a tržby 5,63 miliardy USD, obojí nad odhady. Zisk na akcii tak meziročně vzrostl z 4,02 USD. THC Tenet Healthcare Corporation	FMP Stock News	78
Original source text Tenet Healthcare (THC - Free Report) came out with quarterly earnings of $6.12 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $4.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this hospital operator would post earnings of $4.21 per share when it actually produced earnings of $4.82, delivering a surprise of +14.49%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Tenet, which belongs to the Zacks Medical - Hospital industry, posted revenues of $5.63 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.40%. This compares to year-ago revenues of $5.27 billion. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Tenet shares have lost about 1.7% since the beginning of the year versus the S&P 500's gain of 9.6%. What's Next for Tenet?While Tenet has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Tenet was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.22 on $5.47 billion in revenues for the coming quarter and $17.50 on $22.01 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Hospital is currently in the bottom 10% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Acadia Healthcare (ACHC - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on July 28. This provider of inpatient behavioral health care services is expected to post quarterly earnings of $0.33 per share in its upcoming report, which represents a year-over-year change of -60.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Acadia Healthcare's revenues are expected to be $844.75 million, down 2.8% from the year-ago quarter.
	Saved 2026-07-21 17:33 4d ago Published 2026-07-21 12:46 4d ago	Tenet Healthcare očekává pokles hospitalizačních dnů o 3 % Tenet Healthcare ve 2. čtvrtletí očekává meziroční pokles hospitalizačních dnů o 3 % a kratší délku pobytu. Náklady mají kvůli vyššímu vytížení vzrůst. THC Tenet Healthcare Corporation	FMP Stock News	78
Original source text Key Takeaways Tenet Healthcare reports Q2 results on July 24, with estimates calling for 1.5% EPS and 2.3% revenue growth.THC's Ambulatory Care business is expected to benefit from same-facility revenue growth and acquisitions.Tenet Healthcare faces pressure from lower patient days, shorter stays and higher costs. Hospital operator Tenet Healthcare Corporation (THC - Free Report) is set to report second-quarter 2026 results on July 24, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $4.08 per share on revenues of $5.39 billion. The second-quarter earnings estimate has decreased 3 cents over the past 60 days. Yet, the bottom-line projection indicates a year-over-year increase of 1.5%. Also, the Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 2.3%. Image Source: Zacks Investment Research For full-year 2026, the Zacks Consensus Estimate for Tenet Healthcare’s revenues is pegged at $21.98 billion, implying a rise of 3.1% year over year. The consensus mark for 2026 earnings per share is pegged at $17.50, indicating a jump of 4.3% on a year-over-year basis. Tenet Healthcare beat the consensus estimate for earnings in each of the trailing four quarters, with the average surprise being 20.6%, as you can see below. Q2 Earnings Whispers for THCHowever, our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here. THC has an Earnings ESP of 0.00% and carries a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. What’s Shaping THC’s Q2 Results?The Zacks Consensus Estimate for adjusted patient admissions in total hospital operations suggests a 2.2% year-over-year decline. However, on the same hospital basis, the consensus estimate for adjusted patient admissions indicates a 1% increase from a year ago. The consensus mark for net patient revenues per adjusted admission in the second quarter signals a 10.2% year-over-year increase. Meanwhile, the Ambulatory Care business is likely to have gained from strong growth in consolidated same-facility net patient service revenues, contributions from facility acquisitions and an expansion of service lines. Our model estimate for the Ambulatory Care segment’s net operating revenues suggests 7.8% growth from the prior-year quarter’s figure, whereas the consensus estimate indicates an 8.4% increase. The Zacks Consensus Estimate for adjusted EBITDA from Ambulatory Care operations suggests 5.1% year-over-year growth. The Zacks Consensus Estimate for Hospital Operations and Services revenues for the second quarter is pegged at just a little over $4 billion, indicating a 0.1% increase from the year-ago period. However, the Zacks Consensus Estimate for adjusted EBITDA from the segment suggests a 2.8% year-over-year fall. Both the consensus estimate and our model estimate suggest that second-quarter total hospital patient days have decreased 3% year over year. Both the Zacks Consensus Estimate and our model estimate for the average length of stay in total hospital indicate a 0.2% decrease from a year ago. Also, with increased utilization, costs are expected to have increased in the second quarter, making an earnings beat uncertain. Stocks That Warrant a LookWhile an earnings beat looks uncertain for Tenet Healthcare, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around: ProMIS Neurosciences, Inc. (PMN - Free Report) has an Earnings ESP of +13.30% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for ProMIS’ bottom line for the to-be-reported quarter of a loss of $1.45 indicates an 80% year-over-year improvement. It has witnessed one upward revision against no downward movement over the past 60 days. Alcon Inc. (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank of 2. The Zacks Consensus Estimate for Alcon’s bottom line for the to-be-reported quarter indicates a 1.3% increase from a year ago. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with an average surprise of 3.7%. The consensus estimate for ALC’s revenues is pegged at $2.77 billion, signaling a 7.3% increase. Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2. The Zacks Consensus Estimate for Cardinal Health’s bottom line for the to-be-reported quarter suggests 16.4% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 10.3%. CAH’s revenues for the to-be-reported quarter are pegged at $65.61 billion, a 9.1% increase from the year-ago period.
	Saved 2026-07-11 00:43 15d ago Published 2026-07-10 19:01 15d ago	Tenet Healthcare klesá před výsledky hospodaření Akcie Tenet Healthcare uzavřely na 204,25 USD, což znamená denní pokles o 1,22 % a zaostání za růstem indexu S&P 500 o 0,42 %. Investoři čekají na výsledky hospodaření, které mají být zveřejněny 24. července 2026. THC Tenet Healthcare Corporation	FMP Stock News	72
Original source text Tenet Healthcare (THC - Free Report) closed the most recent trading day at $204.25, moving -1.22% from the previous trading session. This change lagged the S&P 500's 0.42% gain on the day. Meanwhile, the Dow experienced a rise of 0.29%, and the technology-dominated Nasdaq saw an increase of 0.29%. Prior to today's trading, shares of the hospital operator had gained 19.4% outpaced the Medical sector's gain of 5.6% and the S&P 500's gain of 2.2%. Investors will be eagerly watching for the performance of Tenet Healthcare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 24, 2026. The company's upcoming EPS is projected at $4.08, signifying a 1.49% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.39 billion, up 2.27% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.61 per share and a revenue of $22.02 billion, indicating changes of +4.95% and +3.32%, respectively, from the former year. Investors might also notice recent changes to analyst estimates for Tenet Healthcare. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Tenet Healthcare is holding a Zacks Rank of #2 (Buy) right now. With respect to valuation, Tenet Healthcare is currently being traded at a Forward P/E ratio of 11.74. This expresses no noticeable deviation compared to the average Forward P/E of 11.74 of its industry. It is also worth noting that THC currently has a PEG ratio of 1.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Hospital industry had an average PEG ratio of 1.7 as trading concluded yesterday. The Medical - Hospital industry is part of the Medical sector. With its current Zacks Industry Rank of 60, this industry ranks in the top 25% of all industries, numbering over 250. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
	Saved 2026-07-06 17:37 19d ago Published 2026-07-06 11:21 19d ago	Tenet Healthcare zvyšuje odhad zisku díky růstu ambulantní péče Tenet Healthcare těží z rostoucích upravených přijetí a silného růstu ambulantní péče; odhady zisku na akcii pro letošek byly zvýšeny a počítají s růstem o 5 %. THC Tenet Healthcare Corporation	FMP Stock News	78
Original source text Key Takeaways Tenet Healthcare is benefiting from rising adjusted admissions and strong Ambulatory Care growth.THC's earnings estimates moved higher, with projected 5% EPS growth and four straight earnings beats.Tenet Healthcare faces rising operating expenses despite cost-control efforts, posing a margin risk. Tenet Healthcare Corporation (THC - Free Report) is well-poised to grow, backed by the expanding adjusted admissions. Its solid Ambulatory Care segment performance is also a major tailwind. In the year-to-date period, shares of Tenet Healthcare have gained 2.6% against the industry’s 5.5% fall. Headquartered in Dallas, TX, THC operates as a provider of diversified healthcare services and has a market cap of $17.5 billion. Driven by its solid prospects, this Zacks Rank #2 (Buy) stock is worth adding to your portfolio at the moment. Let’s delve deeper. The Zacks Consensus Estimate for Tenet Healthcare’s current-year earnings is pegged at $17.61 per share, which has witnessed two upward estimate revisions in the past 60 days against none in the opposite direction. The estimate indicates 5% year-over-year growth. Tenet Healthcare beat on earnings in all the last four quarters, with an average surprise of 20.6%. The consensus mark for current-year revenues is pegged at $22.02 billion, signaling a 3.3% increase from a year ago. The company’s solid organic growth, supported by rising patient revenue per adjusted admission and a favorable shift toward higher-acuity services, is likely to support the top line. Favorable demographic trends, such as an aging population and rising chronic disease prevalence, are expected to sustain volume growth and support long-term revenue and earnings expansion. THC's performance is benefiting from strong growth in its Ambulatory Care segment, driven by same-facility revenue gains, tuck-in acquisitions of ambulatory surgery centers and surgical hospitals, and continued expansion of the USPI platform. It had interests in 541 ambulatory surgery centers and 26 surgical hospitals in 37 states as of March 31, 2026. Ambulatory net operating revenues increased 17.3% in 2024, 14.1% in 2025 and 10.6% year over year in the first quarter of 2026. THC's return on assets of 5.15% is higher than the industry average of 4.24%, indicating that the company is generating superior returns from its asset base, reflecting stronger operational efficiency and effective capital deployment compared with its peers. Key Risk to MonitorHowever, investors should keep an eye on the company's expense profile. While Tenet Healthcare has implemented cost-control initiatives, including workforce optimization and renegotiated supplier and vendor contracts, expenses have continued to rise. Operating expenses increased 20.6% in 2025 and a further 4.6% year over year in the first quarter of 2026. Total expenses also rose as a percentage of sales. Persistent labor cost pressures, inflation in medical supplies and other inputs, and higher patient acuity are expected to keep expenses elevated, potentially weighing on margins. Other Key PicksSome other top-ranked stocks in the broader Medical space are CVS Health Corporation (CVS - Free Report) , agilon health, inc. (AGL - Free Report) and Biodesix, Inc. (BDSX - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for CVS Health’s 2026 bottom line suggests 10.2% year-over-year growth. CVS has witnessed 12 upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 16.8%. The Zacks Consensus Estimate for agilon health’s full-year 2026 earnings indicates a 92.4% year-over-year improvement. AGL has witnessed two upward estimate revisions over the past 60 days against no movement in the opposite direction. The consensus mark for current-year revenues is currently pegged at $5.72 billion. The Zacks Consensus Estimate for Biodesix’s 2026 full-year earnings implies a 37.7% improvement from the year-ago reported figure. BDSX beat earnings estimates in three of the last four quarters and missed once, with an average surprise of 25.6%. The consensus mark for its current-year revenues is pegged at $110.95 million, which indicates a 25.4% year-over-year increase.
	Saved 2026-07-01 20:16 24d ago Published 2026-07-01 14:06 24d ago	Tenet zvýšil upravenou EBITDA i tržby ve stejných zařízeních Tenet Healthcare prostřednictvím USPI zvýšil ve 1. čtvrtletí 2026 upravenou EBITDA o 6,1 % na 484 milionů USD a tržby ve stejných zařízeních o 5,3 %. Firma zároveň investovala 125 milionů USD do sedmi akvizic ASC a tří nových center. THC Tenet Healthcare Corporation	FMP Stock News	78
Original source text Key Takeaways Tenet Healthcare's USPI delivered 6.1% adjusted EBITDA growth despite weather-related disruptions. THC invested $125M in seven ASC acquisitions and three de novo centers, nearing half its annual plan. Tenet Healthcare says higher-acuity outpatient procedures are strengthening growth and profitability. The next phase of Tenet Healthcare Corporation’s (THC - Free Report) growth is increasingly unfolding beyond its hospitals. Through United Surgical Partners International (“USPI”), Tenet is expanding its ambulatory surgery center (ASC) network to benefit from the healthcare industry's steady shift toward lower-cost outpatient care. As higher-acuity procedures continue shifting to outpatient settings, USPI is becoming an increasingly important driver of long-term growth. That strategy is already translating into strong results. In the first quarter of 2026, USPI generated $484 million in adjusted EBITDA, up 6.1% year over year, while same-facility revenues increased 5.3%. The business also posted double-digit growth in outpatient joint replacements, reflecting rising demand for higher-acuity procedures. Despite weather-related disruptions, USPI delivered a stronger-than-expected quarter, underscoring the strength of the business. Tenet is backing that momentum with continued investment. It invested $125 million during the quarter to acquire seven ASCs and open three de novo centers, completing nearly half of its planned annual investment. A healthy acquisition pipeline, coupled with reaffirmed full-year guidance, reflects confidence in USPI's long-term growth trajectory. More importantly, USPI is helping reshape Tenet's portfolio. By expanding higher-acuity outpatient services, the company enables more complex procedures to be performed in lower-cost settings, supporting long-term growth and profitability. As the shift toward outpatient care continues, USPI is well positioned to remain a key driver of Tenet's long-term growth and shareholder value. How Do Peers Compare?Tenet is not alone in capitalizing on the shift toward outpatient care. Medical peers such as Surgery Partners, Inc. (SGRY - Free Report) and HCA Healthcare, Inc. (HCA - Free Report) are also expanding their outpatient surgery networks to meet growing demand for lower-cost, high-quality surgical care. Surgery Partners continues to expand its ambulatory surgery center network through acquisitions, physician partnerships and a growing focus on higher-acuity procedures. SGRY's strategy reflects the increasing demand for outpatient surgical care and reinforces the long-term growth potential of the ASC market. HCA Healthcare continues investing in ambulatory surgery centers and outpatient facilities while expanding higher-acuity service lines. HCA is also increasing capacity across its outpatient network to support future patient demand and long-term growth. THC’s Price Performance, Valuation & EstimatesShares of Tenet Healthcare have gained 8.6% over the past year compared to the industry's 4.3% decline over the same period. Image Source: Zacks Investment Research From a valuation standpoint, THC trades at a forward price-to-earnings ratio of 10.62X, up from the industry average of 9.06X. THCcarries a Value Score of A. Image Source: Zacks Investment Research The Zacks Consensus Estimate for THC’s 2026 earnings is pegged at $17.61 per share, implying a 4.9% jump from the year-ago period’s level. Image Source: Zacks Investment Research THC currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.